Illumina was right at the core of a plan unveiled in August 2014 by the U.K. government to map 100,000 human genomes by 2017. Its early role focused on whole genome sequencing, but now the genomics giant has also been tapped for bioinformatics as well.
The U.K.'s National Health Service hasn't exactly earned high marks so far for its efforts on the digital health front. Its prior efforts to convert to electronic medical records have failed. But the health program is redoubling its efforts now by committing £4.2 billion ($6 billion) to a variety of digital health initiatives. That news comes on the heels of the agency announcing a series of 7 med tech-focused trials with major technology partners including Alphabet's Verily, Royal Philips and Accenture.
The U.K.'s National Health Service has awarded £240,000 ($340,000) to several med tech researchers.
The United Kingdom's National Health Service sees med tech as crucial to addressing healthcare improvements. It's launched a series of 7 trials with several major technology partners designed to test several means of integrating med tech specifically into at-home care for elderly and chronic disease patients.
A British consortium plans to spend $1.5 billion to bring 11 NHS-related facilities to India, according to a report by the Economic Times.
England may have been behind the U.S. in shining the light on financial ties between pharma and physicians, but that's changing. Not only will National Health Service doctors be required to declare all gifts they receive from drugmakers. They'll also face losing their jobs--or even jail--if pharma payments influence their work.
Startup Touch Bionics has launched its i-limb quantum, the first upper limb prosthesis that can change grips with a small gesture. The U.K.-based startup was the first spinoff from that country's National Health Service via Scottish Health Innovations in 2003. Founded by inventor David Gow, it is backed by Archangel Investors and Scottish Enterprise.
Drugmakers want market access and reimbursement for their new products as fast as possible, and now, the U.K.'s National Institute for Health and Care Excellence is setting up an office with the same goal.
Johnson & Johnson's Janssen unit has agreed to offer England's National Health Service a money-back guarantee on its hep C fighter Olysio, even as the treatment won approval from the cost watchdog there.
Last week, British officials unveiled plans to toss out certain meds from the Cancer Drugs Fund, which covers drugs rejected by the country's cost-effectiveness gatekeepers. Now, the industry is calling for an overhaul in the way pricey cancer drugs are evaluated by the National Institute for Health and Care Excellence.